Navigation Links
The Market for Disease-Modifying Osteoarthritis Drugs Will Experience Exponential Growth, Increasing From $477 Million in 2007 to Nearly $3.8 Billion in 2017
Date:10/8/2008

Extensive Need for Disease-Modifying Agents Creates Significant Opportunity for Drug Developers, According to a New Report from Decision Resources

WALTHAM, Mass., Oct. 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite the anticipated approval of only one disease-modifying therapy over the next decade, the market for disease-modifying osteoarthritis drugs will experience exponential growth, increasing from $477 million in 2007 to nearly $3.8 billion in 2017.

The new Pharmacor report entitled Osteoarthritis: Disease-Modifying Therapies, finds that, following its anticipated approval in 2011, the uptake of Servier's Protelos, as well as off-label use of Novartis/Nordic Bioscience/Emisphere Technologies' SMC-021 for its disease-modifying potential, will drive the tremendous growth of the osteoarthritis drug market through 2017. Market growth will also be fueled by increasing prevalence of osteoarthritis and an increase in drug-treatment rates in the United States and Europe as patients switch from over-the-counter agents with unproven efficacy to new prescription drugs that promise to slow structural progression and improve symptoms of the disease. According to the report, there are 37 million patients diagnosed with osteoarthritis in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The report finds that, owing to the need for disease-modifying drugs, significant opportunity remains for developers of osteoarthritis drugs. Additionally, although some studies have suggested that glucosamine, chondroitin sulfate, diacerein and avocado soybean unsaponifiables may slow the structural progression of osteoarthritis, these agents are not widely accepted as disease-modifying therapies.

"Because of the controversy surrounding the efficacy of agents such as glucosamine or chondroitin sulfate, physicians' responses
'/>"/>

SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
4. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
5. Sodexho, Inc. Announces Patrick E. Connolly as Market President & COO
6. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Paramount Acquisition Corp. Announces Chem Rx Expansion into Albany, New York Market
9. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
10. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
11. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... of the antidepressant Lexapro appears to help prevent ... study finds. The condition is known ... people with this condition may not develop noticeable ... blood supply, according to researchers from Duke University ... the researchers found that people taking the antidepressant ...
(Date:5/22/2013)... By Dennis Thompson HealthDay Reporter , , TUESDAY, ... Americans isn,t improving much, with about six in 10 ... in unhealthy behaviors like smoking, heavy drinking or not ... Tuesday by the U.S. Centers for Disease Control and ... of the lifestyle choices that have led to soaring ...
(Date:5/22/2013)... May 22 (HealthDay News) -- Roughly four in 10 ... pulmonary disease (COPD) actually do not have the lung ... Faulty diagnoses were made based on an evaluation of ... standard" disease test known as spirometry, which shows how ... amount of air they can exhale and how long ...
(Date:5/22/2013)... Atlanta, GA (PRWEB) May 22, 2013 ... marketing agency, JD Media Surge, LLC, E-Dentists.com has ... subjects. The blog will feature numerous topics of ... on treatment options and dental health. , ... element of dental Internet marketing. In addition to ...
(Date:5/22/2013)... Macedon, NY (PRWEB) May 22, 2013 ... other lean manufacturing improvements use the new Do-Done StepTracker ... coordination. “We use the Do-Done board to display the ... Each of our production cells and departments is listed ... top. As we start a project, the squares are ...
Breaking Medicine News(10 mins):Health News:Antidepressants May Be Helpful for Some Heart Patients: Study 2Health News:Antidepressants May Be Helpful for Some Heart Patients: Study 3Health News:Americans Still Making Unhealthy Choices: CDC 2Health News:Americans Still Making Unhealthy Choices: CDC 3Health News:COPD May Be Over-Diagnosed Among Uninsured 2Health News:Dental SEO Blog Launched by E-Dentists.com in Partnership with JD Media Surge, LLC 2Health News:Project Managers Organize Manufacturing Projects and Training with the New Steptracker Project Status Magnetic Whiteboards 2
... N.J., July 9 Red wine (resveratrol) pills appear to be ... to lead the way for patients and consumers to learn more ... do so. , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090709/LA44390 ) , ... of red wine pills, a local cardiology group says it will ...
... Today Americans United for Life (AUL) President & CEO Dr. ... members, urging them to ask Judge Sotomayor the "Top Ten" most ... the Court as the Senators prepare for her confirmation hearings to ... CEO Dr. Charmaine Yoest said, "It,s important for the American people ...
... As part of its Patient Voices series, ... is featuring the stories of people from across the country who ... Patient Voices seeks to give a glimpse into the life ... diverse as the disease itself, and include actress/model and Lupus Foundation ...
... 1 diabetes or having a preceding infection are associated with more ... 49 years old, according to a Finnish study. Furthermore, heart failure ... cancer malignancy with 16 times the risk of death in stroke ... group, said Jukka Putaala, M.D., who led the study. Risk of ...
... The President of the American Chemical Society, ... President Obama,s nomination of Francis Collins, M.D., Ph.D., to ... other time in recent memory has there been such a ... of science to deliver solutions to the grand challenges facing ...
... hits $42 million a year , THURSDAY, July 9 (HealthDay News) ... at least $42 million a year, a new study finds. , ... 100,000 young people annually, said Dr. Warren Lo, lead author of ... but there is growing concern about the cost of medical care ...
Cached Medicine News:Health News:Local Heart Doctors First in Nation to Announce Active Investigation of Red Wine (Resveratrol) Pills, Issue Consumer Precautions 2Health News:Local Heart Doctors First in Nation to Announce Active Investigation of Red Wine (Resveratrol) Pills, Issue Consumer Precautions 3Health News:Local Heart Doctors First in Nation to Announce Active Investigation of Red Wine (Resveratrol) Pills, Issue Consumer Precautions 4Health News:AUL President to Senate Judiciary Committee: Ask Top 10 Questions to Judge Sotomayor 2Health News:The New York Times Website Patient Voices Series Features People Affected by Lupus 2Health News:Stroke in Children Rare But Costly 2Health News:Stroke in Children Rare But Costly 3
(Date:5/22/2013)... 22, 2013 MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) ... about some recent company developments. As Medifirst continues to ... communication with shareholders. Integrating social media into its investor ... and will post updates on Twitter.  The Facebook homepage ... Says CEO Bruce J. ...
(Date:5/22/2013)... --  Life Line Screening  (LLS), a leading national ... of a unique partnership with MCM Solutions for ... a population health management organization. LLS will provide health ... important expanded services will help MCM and its clients ... cost of care when individuals are able to address ...
(Date:5/22/2013)... , May 22, 2013  Generex Biotechnology Corporation ... demonstrating the superiority of the AE37 breast cancer vaccine ... ( www.antigenexpress.com ). The presentations will be made at ... Oncology (ASCO) to be held in Chicago ... The presentation entitled " Booster inoculations of ...
Breaking Medicine Technology:Medifirst Solutions, Inc. Announces Update To Shareholders 2Life Line Screening and MCM Solutions for Better Health Announce New Partnership 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: